Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (41)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lee, S M
Right arrow Articles by Thatcher, N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, S M
Right arrow Articles by Thatcher, N
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 51:609-630 (1995)
© 1995 The British Council

research-article

Melanoma: chemotherapy

S M Lee, D C Betticher and N Thatcher

CRC Department of Medical Oncology, Christie Hospital NHS Trust Manchester M20 4BX

Abstract

The Overall median survival of patients with systemic metastasis from melanoma is about 6 months. Survival is dependent on the sites of first metastasis, the resectability of the metastases, and the number of metastases. Patients with non-visceral metastases at first relapse i.e. in skin, subcutaneous tissues, distant lymph nodes, and lung, have a better survival rate than patients with visceral (liver, bone, brain) metastases. Treatment of patients with systemic melanoma should include careful evaluation for the potential role of surgery, radiotherapy, and systemic therapy. The main use of chemotherapy in metastatic melanoma patients remains palliative. The chapter reviews the chemotherapeutic options available for the treatment of malignant melanoma including recent published works on new agents, multi-agent therapy, high dose chemotherapy with autologous bone marrow rescue, adjuvant chemotherapy and regional perfusion chemotherapy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
D. Bafaloukos, D. Tsoutsos, H. Kalofonos, S. Chalkidou, P. Panagiotou, E. Linardou, E. Briassoulis, E. Efstathiou, A. Polyzos, G. Fountzilas, et al.
Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group
Ann. Onc., June 1, 2005; 16(6): 950 - 957.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. S. Agarwala, J. M. Kirkwood, M. Gore, B. Dreno, N. Thatcher, B. Czarnetski, M. Atkins, A. Buzaid, D. Skarlos, and E. M. Rankin
Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study
J. Clin. Oncol., June 1, 2004; 22(11): 2101 - 2107.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Danson, P. Lorigan, A. Arance, A. Clamp, M. Ranson, J. Hodgetts, L. Lomax, L. Ashcroft, N. Thatcher, and M.R. Middleton
Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma
J. Clin. Oncol., July 1, 2003; 21(13): 2551 - 2557.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Ridolfi, V. Chiarion-Sileni, M. Guida, A. Romanini, R. Labianca, A. Freschi, G. Lo Re, R. Nortilli, S. Brugnara, P. Vitali, et al.
Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial
J. Clin. Oncol., March 15, 2002; 20(6): 1600 - 1607.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Bafaloukos, H. Gogas, V. Georgoulias, E. Briassoulis, G. Fountzilas, E. Samantas, Ch. Kalofonos, D. Skarlos, A. Karabelis, and P. Kosmidis
Temozolomide in Combination With Docetaxel in Patients With Advanced Melanoma: A Phase II Study of the Hellenic Cooperative Oncology Group
J. Clin. Oncol., January 15, 2002; 20(2): 420 - 425.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.